Results 61 to 70 of about 9,532 (171)

Pomalidomide enhances CD8+ T and NK cell mediated killing of HIV-infected cellsResearch in context

EBioMedicine
Summary: Background: Overcoming persisting immune dysfunction in people living with HIV (PLHIV) on suppressive antiretroviral therapy (ART) is a key challenge to curing HIV.
Rachel D. Pascoe, Celine Gubser, J. Judy Chang, Jan Schröder, Daniel T. Utzschneider, Alexander Barrow, Wen Shi Lee, James H. McMahon, Chris Y. Chiu, Ajantha Solomon, Jenny Anderson, Sharon R. Lewin, Thomas A. Rasmussen   +12 more
doaj   +1 more source

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice

, 2011
Pharmacologic induction of fetal hemoglobin (HbF) expression is an effective treatment strategy for sickle cell disease (SCD) and β-thalassemia. Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs.
Laure A. Moutouh-de Parseval, Laura G. Corral, Steffen E. Meiler, Paul S. Swerdlow, Shobha D. Yerigenahally, Ferdane Kutlar, Yongjun Xue, Marlene Wade, Abdullah Kutlar   +8 more
core   +1 more source

Pomalidomide Desensitization in a Patient Hypersensitive to Immunomodulating Agents

, 2017
Despite progressive treatments with tandem stem-cell transplantation, patients with incurable myeloma eventually succumb to relapsed or refractory disease if left untreated. Promising agents such as proteasome inhibitors and immunomodulating imide drugs (
J.T. Seki, W. Lam, N. Sakurai, D.E. Reece   +3 more
core   +1 more source

Inhibition of Airway Contraction and Inflammation by Pomalidomide in a Male Wistar Rat Model of Ovalbumin-induced Asthma

Iranian Journal of Allergy, Asthma and Immunology, 2019
Asthma is a chronic inflammatory disease of the airways of the lungs. Pomalidomide (POM) a therapy for multiple myeloma has been stated to have an anti-inflammatory effect.
Majid Ghaderi, Shahrbanoo Oryan, Namdar Yousofvand, Akram Eidi   +3 more
doaj   +1 more source

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

British Journal of Haematology, EarlyView.
Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang, Wei Wang, Wenming Chen, Yanping Ma, Rong Fu, Junling Zhuang   +15 more
wiley   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Versatile Detection of Cellular Protein via Fluorescence Anisotropy

Advanced Science, Volume 13, Issue 51, 14 September 2026.
Cell Lysate Fluorescence Anisotropy (CFAST) utilizes long lifetime dye‐labeled nanobodies for rapid protein quantification in minimally purified, complex cell lysate. When coupled with cellular thermal shift, CFAST allows high‐throughput detection of endogenous protein‐small molecule engagement, facilitating the discovery of novel binders for ...
Qing Tang, Yuan‐Ping Wei, Ricky Ruiqi Ma, Na Wei, Tammy Zihan Zhou, Hilary Kung‐Yu Ho, Zafar Iqbal Bhat, Iqra Ishrat, Xiaoyu Li, Judy Wai Ping Yam, Yung Hou Wong, Qiankun Wang, Justin L. Tan   +12 more
wiley   +1 more source

3,6’-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation

eLife, 2020
Traumatic brain injury (TBI) causes mortality and disability worldwide. It can initiate acute cell death followed by secondary injury induced by microglial activation, oxidative stress, inflammation and autophagy in brain tissue, resulting in cognitive ...
Chih-Tung Lin, Daniela Lecca, Ling-Yu Yang, Weiming Luo, Michael T Scerba, David Tweedie, Pen-Sen Huang, Yoo-Jin Jung, Dong Seok Kim, Chih-Hao Yang, Barry J Hoffer, Jia-Yi Wang, Nigel H Greig   +12 more
doaj   +1 more source

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Haematologica
Background. Inobrodib (CCS1477; Ino) is a first-in-class, potent, selective, orally bioavailable inhibitor of the bromodomains of p300 and CBP, histone acetyltransferases with oncogenic roles in haematologic malignancies.
E. Searle, V. Campbell, C. Pawlyn, D. Vogl, S. Holstein, S. Gooding, M. Jenner, T. Creasey, A. Chaidos, P. Rodríguez-Otero, F. Al-Kaisi, A. Brearton, S. Moore, J. O’Nions, T. Somervaille, T. Knurowski, K. Clegg, S. Paul, K. Frese, N. Joseph   +19 more
doaj   +1 more source

Efficacy, safety and cost of pomalidomide in relapsed and refractory multiple myeloma

, 2018
IF 2.653International audienceObjectivesTo investigate the efficacy, safety and cost of a pomalidomide-dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM).MethodsAll patients (n=63) treated with pomalidomide ...
Amelie Cransac-Miet, Camille Favennec, Chrétien, Marie-Lorraine, Caillot, Denis, Aho, Ludwig, Pauline Gueneau, Denis Caillot, Guy, Julien, Marie-Lorraine Chretien, Ingrid Lafon, Lafon, Ingrid, Favennec, Camille, Cansac-Miet, Amelie, Boulin, Mathieu, Julien Guy, Mathieu Boulin, Gueneau, Pauline, Ludwig Serge Aho   +17 more
core   +1 more source